| abstract |
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula:n nwherein: A is an aryl group; Q 1 is an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: -NR 1 (=O)- and -C(=O)NR 1 -; R 1 is an amido substituent; and, Q 2 is an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, and ethers thereof, for use in the treatment of a fibroproliferative disorder; liver fibrosis; smooth muscle proliferative disorder; atherosclerosis; restenosis; a neurodegenative disease; Alzheimer's; Parkinson's; Huntington's chorea; amyotropic lateral sclerosis; spino-cerebellar degeneration; an inflammatory disease; osteoarthritis; rheumatoid arthritis; a diseases involving angiogenesis; diabetic retinopathy; a haematopoietic disorder; anaemia; sickle cell anaemia; thalassaeimia; a fungal infection; a parasitic infection; trypanosomiasis; helminthiasis; a protozoal infection; a bacterial infection; a viral infection; a condition treatable by immune modulation; multiple sclerosis; autoimmune diabetes; lupus; atopic dermatitis; an allergy; asthma; allergic rhinitis; or inflammatory bowel disease. |